Compare IDCC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | IOVA |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.7B |
| IPO Year | 2007 | 2008 |
| Metric | IDCC | IOVA |
|---|---|---|
| Price | $317.18 | $8.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $462.67 | $14.30 |
| AVG Volume (30 Days) | 161.0K | ★ 13.5M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 7.86 | N/A |
| Revenue | ★ $307,404,000.00 | N/A |
| Revenue This Year | N/A | $57.19 |
| Revenue Next Year | N/A | $43.78 |
| P/E Ratio | $40.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $249.14 | $1.76 |
| 52 Week High | $387.30 | $15.37 |
| Indicator | IDCC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 31.66 |
| Support Level | $293.62 | $7.85 |
| Resistance Level | $348.21 | $9.36 |
| Average True Range (ATR) | 12.48 | 1.00 |
| MACD | -1.49 | -0.93 |
| Stochastic Oscillator | 9.30 | 9.87 |
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.